Table of Contents
Let’s Start by Clearly Breaking Down Skin Boosters
You’ve probably heard the term ‘skin booster’ a lot at Korean dermatology clinics. But here’s the thing—it’s not a single ingredient or a legally defined product category. It’s more of a market term that loosely groups together various procedures aimed at improving skin conditions like hydration, texture, elasticity, and wrinkles by injecting hyaluronic acid, polynucleotides, poly-L-lactic acid derivatives, or extracellular matrix components into the skin.
Compared to botulinum toxin, which reduces muscle movement, or fillers that add volume to tissues, skin boosters focus on improving skin condition. That said, some products can also have volumizing or collagen-stimulating effects, so the lines aren’t always crystal clear. Even when marketed under the same ‘skin booster’ label, ingredients, approved uses, injection depth, and side effects can all vary.
In the Korean market, this category took off quickly after Pharmaresearch launched Rejuran in 2014. Some industry reports cite an average annual growth rate of 46.4% for the domestic market, but these aren’t official public statistics with a clear collection period or product scope—so take them as rough references. Market size can swing wildly depending on whether you lump in fillers and collagen stimulators.
The claim that the global market is growing at over 15% annually to reach tens of trillions of won by 2030 doesn’t match the cited market data. According to Straits Research, cited by Chosun Biz and Dong-A Business Review, the global market is projected to grow from $1.78 billion in 2025 to $2.69 billion by 2030—about 3.9 trillion won. That translates to an average annual growth rate of 8.6%.
Re2O Is a Broader Concept Than Just a ‘Collagen Injection’
‘Elravie Re2O,’ developed by L&C Bio and distributed by Humedix, launched in Korea on November 18, 2024. Its key ingredient is hADM—acellular dermal matrix from human donors. It’s human tissue from deceased donors, processed to remove cells that could trigger immune reactions while preserving the structural framework, the extracellular matrix.
The extracellular matrix isn’t just collagen. It also contains elastin, glycoproteins, glycosaminoglycans, and other components that make up the skin’s structure and environment. Re2O processes this tissue into microparticles, which are hydrated with saline during the procedure and injected into the skin. So calling it ‘injecting collagen’ doesn’t really capture the product’s full nature.
The company claims Re2O is the world’s first hADM-based ECM skin booster. But ‘world’s first’ is their marketing language—don’t take it as an independently verified international status. Rejuran uses polynucleotides from salmon DNA, Juvelook uses poly-D,L-lactic acid and hyaluronic acid, and Sculptra uses poly-L-lactic acid as a collagen stimulator. Instead of lumping them all together as ‘synthetic or animal-derived products,’ it’s more accurate to break down each ingredient and mechanism separately.
A randomized, split-face study published in an international journal in 2026 compared microparticulate hADM (the kind used in Re2O) with hyaluronic acid over 20 weeks in 20 adults. The researchers reported greater improvements in skin density, elasticity, pore area, and hydration with hADM, with no serious adverse events. But this is an early study with just 20 participants and a 20-week observation period. Don’t overinterpret it as proof of rare side effects, long-term durability over years, or safety across diverse ages and skin conditions.
It Sold Fast, But Check the Reference Year for the Numbers
There’s evidence behind the claim that market response was swift. Company and securities reports say Re2O was supplied to over 1,000 medical institutions within about 8 months of launch. But keep in mind—this figure is based on the company’s sales data, not an independent census of all medical institutions. And the number of supplied institutions doesn’t prove actual procedure volumes or clinical efficacy.
L&C Bio raised its 2025 sales target for Re2O from 3 billion won to 5 billion won as sales picked up. That’s an increase of about 66.7%, not ‘more than double.’ The company later set a 2026 sales target of 50 billion won and expanded production capacity. Mixing targets from different years can exaggerate growth rates, so keep them separate.
In December 2025, ‘Elravie Re2O Fine’ was added. The original product has an average particle size of about 100㎛ and a dose of 150mg, while Fine uses particles averaging about 50㎛ and a 50mg dose. In terms of dosage, it’s one-third of the original. But a smaller dose doesn’t automatically mean higher profitability or better results. It’s more accurate to describe it as a separate specification tailored to different injection sites and purposes.
The company’s overall financials also need a timeline correction. The 72.1 billion won in revenue and 2.5 billion won in operating profit are consolidated 2024 figures. After Re2O’s launch, 2025 annual revenue was reported at 85.5 billion won, up about 18.5% from the previous year. So presenting the 72.1 billion won and 2.5 billion won as current 2026 figures would be a timing mismatch.
Overseas, the company introduced Re2O at the ‘MSAAH Congress 2026’ in Yangon, Myanmar on May 19, 2026. That means they held a product launch session at a local conference. But whether they can officially sell in Myanmar or other countries depends on each nation’s regulations for human tissue and medical products and registration procedures. Just attending a conference doesn’t mean overseas approvals or market entry are complete.
It’s Not ‘Unregulated,’ but It’s Managed Differently from Medical Devices
The core of the Re2O debate is that its raw material is donated human tissue and its domestic regulatory classification. Re2O is classified as human tissue, not a drug or medical device. It’s regulated under the Human Tissue Safety and Management Act, covering tissue bank licensing, donor suitability checks, infectious disease testing, and processing, storage, and distribution standards. So calling it an unregulated product is inaccurate.
But it doesn’t go through the same process as medical devices. Medical devices require item-level approval after review of intended use, performance, and safety data. Human tissue is managed around tissue banks, manufacturers, and tissue type. Re2O could be supplied to clinics without separate product-level medical device approval or mandatory clinical trials for approval. This is why the debate over fairness and safety has emerged—whether it’s appropriate for a substance injected into the skin to be managed at a different level than other skin boosters.
This issue gained widespread attention through a Chosun Biz report on March 3, 2026, and has since been discussed in the National Assembly, consumer groups, and the medical community. The Ministry of Food and Drug Safety has said it’s considering measures like notifying consumers about human tissue origin, restricting cosmetic advertising, expanding adverse event reporting procedures, and including the purpose of use in tissue transplant records. Distinguish between the government reviewing stronger oversight and the product currently being illegal. The company maintains that it manufactures and distributes the product legally under current laws.
When it comes to donor consent, look at both sides. Critics argue that the human tissue donation system was built on the public good of restoring bodily functions like treating burns, wounds, and reconstruction—and using it for cosmetic procedures may not align with that intent. L&C Bio, on the other hand, says it sources 100% of its raw material from the U.S., where the donation process clearly distinguishes whether the tissue can be used for cosmetic purposes. It’s not prudent to assume all donors consented only for therapeutic use, nor to conclude that the company’s explanation fully resolves ethical concerns.
Before Getting Treated, Check the Source, Disclosure, and Evidence
If you’re considering Re2O, first make sure you’re clearly informed that it’s a human tissue-derived product. Some people may want to avoid human-derived materials for religious or personal reasons. Ask your doctor specifically about the product name, raw material, domestic regulatory classification, expected effects and limitations, possible adverse reactions, and what to do if something goes wrong.
Don’t generalize that ‘skin boosters always require multiple sessions.’ The recommended intervals and number of sessions vary by product, injection volume, skin condition, and treatment goals. Check whether the package your clinic offers is medically necessary or an optional plan. When calculating costs, consider not just the per-session price but also the planned number of sessions and follow-up care.
When consulting about efficacy, it’s important to distinguish between company promotional materials and clinical studies. The fact that human research on Re2O has been published means there’s more evidence than before. But a 20-person, 20-week study isn’t enough to establish long-term safety. If you have existing allergies, immune conditions, skin infections, or are taking medications that affect bleeding risk, be sure to tell your doctor before the procedure.
The question Re2O raises isn’t just about whether it works well or not. It’s about how far donated human tissue can be used for cosmetic purposes, whether it’s appropriate to apply different review systems for medical devices versus human tissue, and what level of disclosure consumers should receive about the source of the raw material. Evaluating the potential of a new regenerative material and strengthening donation ethics and safety management standards need to go hand in hand.
Sources: Chosun Biz, ‘Donated Cadaver Skin Turned into 80 Billion Won Cosmetic Injections… L&C Bio’s Re2O Regulatory Gap Controversy,’ March 3, 2026; Yonhap News, ‘Strengthening Management of Human Tissue Skin Boosters… Pushing for Advertising Restrictions,’ March 29, 2026; Chosun Biz, ‘Re2O Skin Booster Made from Cadaver Skin in Regulatory Blind Spot,’ April 16, 2026; The Bell, ‘L&C Bio, Spreading Risk Globally Amid Tightening Regulatory Pressure,’ April 2026; L&C Bio press release, November 18, 2024; Hana Securities L&C Bio Company Analysis, May 2026; International Journal of Molecular Sciences, ‘Injectable Particulated Human Acellular Dermal Matrix Booster for Skin Restoration,’ 2026; MSAAH Congress 2026 official guide.
